{"entity":{"id":"nct04458272","kind":"trial","name":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","aka":[],"tldr":"A phase 2 trial of Safusidenib in glioma & glioblastoma, run by Daiichi Sankyo Co., Ltd., active and no longer recruiting.","summary":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma is a phase 2 interventional study registered as NCT04458272 by Daiichi Sankyo Co., Ltd., with 25 participants enrolled, started 2020-07-08 and due to reach its primary completion in 2023-03-10. Interventions recorded: DS-1001b.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04458272","url":"https://clinicaltrials.gov/study/NCT04458272"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["safusidenib"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04458272","phase":"2","setting":"A Phase II Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-naive IDH1 Mutated WHO Grade II Glioma","sponsor":"Daiichi Sankyo Co., Ltd.","enrolled":25,"outcomes":[]},"route":"/trials/nct04458272/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}